Other non-immunosuppressive CypA inhibitors, NIM811 and SCY-635, inhibit hepatocarcinogenesis by disrupting CypA-NS5A interaction in hepatitis C virus-induced hepatocellular carcinoma [97]. Here, PPIA is linked to hepatocellular carcinoma.